Systemic Bio to Present Innovative Human-relevant Datasets from h-VIOS™ Platform at SOT and AACR 2024 Annual Meetings
February 08 2024 - 8:30AM
Systemic Bio™, a 3D Systems (NYSE:DDD) company, is excited to
announce the acceptance of two abstracts for presentation at the
prestigious Society of Toxicology (SOT) 2024 Annual Meeting (Salt
Lake City, March 10-14, 2024) and American Association for Cancer
Research (AACR) 2024 Annual Meeting (San Diego, April 5-10, 2024).
At the SOT 2024 meeting, Systemic Bio will present its latest
research on an advanced liver model that demonstrates several-fold
enhanced albumin production, CYP (cytochrome P450) activity, and
urea production compared to traditional models. This innovative
model offers substantial improvements in assessing Drug-Induced
Liver Injury (DILI) and Drug Metabolism and Pharmacokinetics
(DMPK), marking a significant step forward in liver toxicity
testing and drug safety evaluation.
The second abstract, accepted for AACR 2024, showcases a novel
model that simultaneously assesses on-target anti-tumor therapeutic
efficacy and off-target liver injury of therapeutics across
different modalities. This cutting-edge development features
connected tissues and is modality-agnostic, allowing for
comprehensive evaluation of cancer treatments and their impacts on
the liver, a critical aspect in oncology drug development. To delve
deeper into this research, all conference attendees and fellow
researchers can visit booth #4452 to engage directly with Systemic
Bio’s team and discover the full potential of the h-VIOS
platform.
SOT presentation details:Presenter: Cristiana Trinconi,
PhDSession Date and Time: March 13, 2024, 11:45 AM - 1:45
PMLocation: P488
AACR presentation details:Presenter: Juliana Navarro-Yepes,
PhDSession Date and Time: April 10, 2024, 9:00 AM - 12:30
PMLocation: Board Number 1, Poster Section 6
For more information about Systemic Bio and its pioneering work,
please visit www.systemic.bio.
Forward-Looking StatementsCertain statements
made in this release that are not statements of historical or
current facts are forward-looking statements. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or
achievements of Systemic Bio or 3D Systems, as applicable, to be
materially different from historical results or from any future
results or projections expressed or implied by such forward-looking
statements. In many cases, forward-looking statements can be
identified by terms such as "believes," "belief," "expects," "may,"
"will," "estimates," "intends," "anticipates" or "plans" or the
negative of these terms or other comparable terminology.
Forward-looking statements are based upon management’s beliefs,
assumptions, and current expectations and may include comments as
to the beliefs and expectations of Systemic Bio or 3D Systems as to
future events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside the control of
the applicable company. The factors described under the headings
"Forward-Looking Statements" and "Risk Factors" in 3D Systems’
periodic filings with the Securities and Exchange Commission, as
well as other factors, could cause actual results to differ
materially from those reflected or predicted in forward-looking
statements. Although management believes that the expectations
reflected in the forward-looking statements are reasonable,
forward-looking statements are not, and should not be relied upon
as a guarantee of future performance or results, nor will they
necessarily prove to be accurate indications of the times at which
such performance or results will be achieved. The forward-looking
statements included are made only as of the date of the statement.
Neither Systemic Bio nor 3D Systems undertakes any obligation to
update or revise any forward-looking statements made by management
or on its behalf, whether as a result of future developments,
subsequent events or circumstances or otherwise, except as required
by law.
About Systemic BioSystemic Bio is a biotech
company focused on accelerating drug discovery and development with
human-relevant data from its proprietary platform of bioprinted
vascularized organ models. Founded in 2022 as a wholly-owned
company of 3D Systems, Systemic Bio leverages 3D Systems’
breakthrough, production-level bioprinting technology to create
extremely precise healthy and diseased tissues using biomaterials
and human cells. These proprietary organs-on-chips can be
manufactured reproducibly in large quantities, and then perfused
with drugs to study the effects on healthy or diseased tissue at
the earliest stages of pharmaceutical drug development. These
systems are multimodal and can be used to generate large datasets
leveraged with machine learning to generate human-relevant
therapeutic insights. More information on the company is available
at www.systemic.bio.
About 3D Systems More than 35 years ago, 3D
Systems brought the innovation of 3D printing to the manufacturing
industry. Today, as the leading additive manufacturing solutions
partner, we bring innovation, performance, and reliability to every
interaction - empowering our customers to create products and
business models never before possible. Thanks to our unique
offering of hardware, software, materials, and services, each
application-specific solution is powered by the expertise of our
application engineers who collaborate with customers to transform
how they deliver their products and services. 3D Systems’ solutions
address a variety of advanced applications in healthcare and
industrial markets such as medical and dental, aerospace &
defense, automotive, and durable goods. More information on the
company is available at www.3dsystems.com.
Investor
Contact: |
investor.relations@3dsystems.com |
Media Contact: |
press@systemic.bio |
3D Systems (NYSE:DDD)
Historical Stock Chart
From Apr 2024 to May 2024
3D Systems (NYSE:DDD)
Historical Stock Chart
From May 2023 to May 2024